Mankind Pharma share price falls 2.14%, stock among top losers on Nifty Midcap 150

Shares of Mankind Pharma declined by 2.14% to Rs 2,551.10 in Monday's session, making it among the top losers on the Nifty Midcap 150 index.

Financial Snapshot:

The following tables summarize the consolidated financial performance of Mankind Pharma.

Quarterly Results:

The revenue for Mankind Pharma has shown an increase in the recent quarters. The revenue for the quarter ending June 2025 stood at Rs 3,570.35 Crore, up from Rs 2,893.42 Crore in June 2024. Similarly, the net profit for the quarter ending June 2025 was Rs 441.45 Crore, compared to Rs 539.16 Crore in June 2024.

Annual Results:

The annual financial results show a consistent increase in revenue and net profit over the years. The revenue for the year ending 2025 was Rs 12,207.44 Crore, compared to Rs 6,214.43 Crore in 2021. The net profit for the year ending March 2025 stood at Rs 1,994.35 Crore, increased from Rs 1,281.36 Crore in 2021.

Standalone Income Statement (Annual):

The standalone annual income statement shows that sales increased from Rs 5,529 Crore in March 2021 to Rs 9,497 Crore in March 2025. The net profit also increased from Rs 1,084 Crore in March 2021 to Rs 1,884 Crore in March 2025.

Standalone Income Statement (Quarterly):

The standalone quarterly income statement shows sales of Rs 2,541 Crore for June 2025 compared to Rs 2,403 Crore for June 2024. The net profit was Rs 412 Crore for June 2025 compared to Rs 513 Crore for June 2024.

Cash Flow:

Balance Sheet:Financial Ratios:Corporate Actions:

Mankind Pharma has been actively involved in several corporate actions. On August 19, 2025, the company announced updates on the acquisition, specifically the incorporation of a wholly-owned subsidiary in Russia. Additionally, the company intimated about the upcoming Investor Meet on August 11, 2025. Furthermore, on August 7, 2025, during the 34th Annual General Meeting (AGM), shareholders approved the appointment of M/s. Amit Gupta & Associates as Secretarial Auditors, a decision previously endorsed by the Board of Directors on May 21, 2025.

Mankind Pharma had declared an interim dividend of Rs 1.00 per share (100%) with the effective date being August 8, 2025.

With the stock's last traded price at Rs 2,551.10, Mankind Pharma has experienced a notable downturn, influenced by bearish investor sentiment, as the stock is among the top losers on the Nifty Midcap 150 index.